From GlobeNewswire: 2025-04-17 09:10:00

The Pacemakers Market was valued at USD 5.35 billion in 2023 and is projected to reach USD 8.77 billion by 2032, growing at a CAGR of 5.66%. Factors driving growth include an increasing burden of cardiovascular disorders, advancements in leadless and MRI-compatible pacemakers, and a growing elderly population.

In the United States, the market size was USD 1.55 billion in 2023 and is expected to reach USD 2.34 billion by 2032, driven by well-developed healthcare infrastructure and early adoption of cutting-edge cardiac devices.

Implantable pacemakers dominated the market in 2023, with a 65.0% share, due to their reliability and minimally invasive procedures. The bradycardia segment had a market share of 24.5%, while hospitals led end-use with a 68.6% share.

North America held a 38.4% share of the global pacemaker market in 2023, driven by positive reimbursement systems and technological advancements. The Asia-Pacific region is expected to see the fastest growth, fueled by investments in healthcare infrastructure and rising awareness of heart health.

Recent developments include Boston Scientific’s FDA safety communication regarding its Accolade pacemakers due to a battery cathode manufacturing issue. In November 2024, Abbott launched the AVEIR VR leadless pacemaker in India, while Medtronic introduced the Micra AV2 and VR2 in select European markets in August 2024. Biotronik also released the Biomonitor IV across Europe in June 2024, enhancing remote monitoring capabilities for patients with bradycardia.

Statistical data from 2023 shows that over 38 million people globally were diagnosed with cardiac arrhythmias, with bradycardia cases representing 15%. North America and Europe had the highest pacemaker implant rates, with the U.S. performing nearly 180 implants per 100,000 people compared to 90 in APAC countries.

Global pacemaker production rose from 1.1 million units in 2020 to 1.6 million units in 2023, with projections to exceed 2.4 million units annually by 2032. In 2023, North America spent over USD 6.8 billion on cardiac rhythm management devices, with government-funded insurance covering 35% of costs, while APAC regions relied more on private payments.

Prescriptions for pacemaker implants increased by 12% in APAC and 8% in Latin America in 2023, reflecting steady demand in Europe and North America due to established healthcare programs. The market dynamics impact analysis and competitive landscape provide insights into technological advancements and innovation trends in pacemakers, as well as patient demographics and acceptance rates.



Read more at GlobeNewswire: Pacemakers Market Size to Hit USD 8.77 Billion by 2032,